Attenuation of amyloid fibrillation in presence of Warfarin: A biophysical investigation

International Journal of Biological Macromolecules

Volumn 95, Issue , 2017, Pages 713-718

  Siddiqi, Mohammad Khursheed ^a   Alam, Parvez ^a   Chaturvedi, Sumit Kumar ^a   Nusrat, Saima ^a   Shahein, Yasser E ^b   Khan, Rizwan Hasan ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Aggregation inhibition; Amyloid fibrils; Amyloidosis; Beta sheet conformation; Congo red binding; ThT binding

Indexed keywords

AMYLOID; HUMAN SERUM ALBUMIN; WARFARIN; PROTEIN AGGREGATE; SERUM ALBUMIN;

AMYLOIDOSIS; ANTI AMYLOIDEGENIC ACTIVITY; ARTICLE; BINDING ASSAY; BINDING SITE; BIOPHYSICS; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; DRUG ACTIVITY; FLUORESCENCE ANALYSIS; HYDROPHOBICITY; PH; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; TRANSMISSION ELECTRON MICROSCOPY; CHEMICAL PHENOMENA; CHEMISTRY; HUMAN; KINETICS;

AMYLOID; BIOPHYSICAL PHENOMENA; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; PROTEIN AGGREGATES; PROTEIN STRUCTURE, SECONDARY; SERUM ALBUMIN; WARFARIN;

EID: 85008627668     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2016.11.110     Document Type: Article

References (49)

1. [1] Hall, D., Kardos, J., Edskes, H., Carver, J.A., Goto, Y., A multi-pathway perspective on protein aggregation: implications for control of the rate and extent of amyloid formation. FEBS Lett. 589 (2015), 672–679.
2. [2] Jucker, M., The amyloid state of proteins in human diseases. Cell 148 (2012), 1188–1203.
3. [3] Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S.I., Merlini, G., Saraiva, M.J.M., Westermark, P., Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19 (2012), 167–170.
4. [4] Ishtikhar, M., Usmani, S.S., Gull, N., Badr, G., Mahmoud, M.H., Khan, R.H., Inhibitory effect of copper nanoparticles on rosin modified surfactant induced aggregation of lysozyme. Int. J. Biol. Macromol. 78 (2015), 379–388.
5. [5] Chiti, F., Stefani, M., Taddei, N., Ramponi, G., Dobson, C.M., Rationalization of the effects of mutations on peptide andprotein aggregation rates. Nature 424 (2003), 805–808.
6. [6] Chiti, F., Dobson, C.M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006), 333–366.
7. [7] Gazit, E., The correctly folded state of proteins: is it a metastable state?. Angew. Chem. Int. Ed. 41 (2002), 257–259.
8. [8] I. Stroke Prevention in Atrial Fibrillation, Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 343 (1994), 687–691.
9. [9] Stein, P.D., Alpert, J.S., Bussey, H.I., Dalen, J.E., Turpie, A.G.G., Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. CHEST J. 119 (2001), 220S–227S.
10. [10] Cairns, J.A., Theroux, P., Lewis, H.D., Ezekowitz, M., Meade, T.W., Antithrombotic agents in coronary artery disease. CHEST J. 119 (2001), 228S–252S.
11. [11] Sinisi, V., Forzato, C., Cefarin, N., Navarini, L., Berti, F., Interaction of chlorogenic acids and quinides from coffee with human serum albumin. Food Chem. 168 (2015), 332–340.
12. [12] Alam, P., Abdelhameed, A.S., Rajpoot, R.K., Khan, R.H., Interplay of multiple interaction forces: binding of tyrosine kinase inhibitor nintedanib with human serum albumin. J. Photochem. Photobiol. B 157 (2016), 70–76.
13. [13] Qi, J., Zhang, Y., Gou, Y., Zhang, Z., Zhou, Z., Wu, X., Yang, F., Liang, H., Developing an anticancer copper (II) pro-drug based on the His242 residue of the human serum albumin carrier IIA subdomain. Mol. Pharm. 13 (2016), 1501–1507.
14. [14] Ajmal, M.R., Abdelhameed, A.S., Alam, P., Khan, R.H., Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 159 (2016), 199–208.
15. [15] Juarez, J., Taboada, P., Mosquera, V., Existence of different structural intermediates on the fibrillation pathway of human serum albumin. Biophys. J. 96 (2009), 2353–2370.
16. [16] Peters, T. Jr, All About Albumin: Biochemistry, Genetics, and Medical Applications. 1995, Academic Press.
17. [17] Duman, O., Tunc, S., Bozoglan, B.K., Characterization of the binding of metoprolol tartrate and guaifenesin drugs to human serum albumin and human hemoglobin proteins by fluorescence and circular dichroism spectroscopy. J. Fluoresc. 23 (2013), 659–669.
18. [18] Anraku, M., Shintomo, R., Taguchi, K., Kragh-Hansen, U., Kai, T., Maruyama, T., Otagiri, M., Amino acids of importance for the antioxidant activity of human serum albumin as revealed by recombinant mutants and genetic variants. Life Sci. 134 (2015), 36–41.
19. [19] Sudlow, G., Birkett, D.J., Wade, D.N., Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12 (1976), 1052–1061.
20. [20] Salvi, A., Carrupt, P.-A., Mayer, J.M., Testa, B., Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid. Drug Metab. Dispos. 25 (1997), 395–398.
21. [21] Tunc, S., Duman, O., Bozoglan, B.K., Studies on the interactions of chloroquine diphosphate and phenelzine sulfate drugs with human serum albumin and human hemoglobin proteins by spectroscopic techniques. J. Lumin. 140 (2013), 87–94.
22. [22] Varshney, A., Ansari, Y., Zaidi, N., Ahmad, E., Badr, G., Alam, P., Khan, R.H., Analysis of binding interaction between antibacterial ciprofloxacin and human serum albumin by spectroscopic techniques. Cell Biochem. Biophys. 70 (2014), 93–101.
23. [23] Jusko, W.J., Gretch, M., Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab. Rev. 5:1 (2008), 43–140.
24. [24] Kragh-Hansen, U., Chuang, V.T.G., Otagiri, M., Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 25 (2002), 695–704.
25. [25] Siddiqi, M.K., Alam, P., Chaturvedi, S.K., Khan, R.H., Anti-amyloidogenic behavior and interaction of diallylsulfide with human serum albumin. Int. J. Biol. Macromol. 92 (2016), 1220–1228.
26. [26] Mao, Y., Teoh, C.L., Yang, S., Zlatic, C.O., Rosenes, Z.K., Gooley, P.R., Howlett, G.J., Griffin, M.D.W., Charge and charge-pair mutations alter the rate of assembly and structural properties of apolipoprotein C-II amyloid fibrils. Biochemistry 54 (2015), 1421–1428.
27. [27] Bhattacharya, M., Mukhopadhyay, S., Studying protein misfolding and aggregation by fluorescence spectroscopy. Reviews in Fluorescence, 2015, Springer, 2016, 1–27.
28. [28] Chaturvedi, S.K., Khan, J.M., Siddiqi, M.K., Alam, P., Khan, R.H., Comparative insight into surfactants mediated amyloidogenesis of lysozyme. Int. J. Biol. Macromol. 83 (2016), 315–325.
29. [29] Alam, P., Chaturvedi, S.K., Siddiqi, M.K., Rajpoot, R.K., Ajmal, M.R., Zaman, M., Khan, R.H., Vitamin k3 inhibits protein aggregation: implication in the treatment of amyloid diseases. Sci. Rep. 6 (2016), 1–11.
30. [30] Brumshtein, B., Esswein, S.R., Salwinski, L., Phillips, M.L., Ly, A.T., Cascio, D., Sawaya, M.R., Eisenberg, D.S., Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain. Elife, 4, 2015, e10935.
31. [31] Marion, J., Trovaslet, M., Martinez, N., Masson, P., Schweins, R., Nachon, F., Trapp, M., Peters, J., Pressure-induced molten globule state of human acetylcholinesterase: structural and dynamical changes monitored by neutron scattering. Phys. Chem. Chem. Phys. 17 (2015), 3157–3163.
32. [32] Siddiqi, M.K., Shahein, Y.E., Hussein, N., Khan, R.H., Effect of surfactants on Ra-sHSPI-A small heat shock protein from the cattle tick Rhipicephalus annulatus. J. Mol. Struct. 1119 (2016), 12–17.
33. [33] Chaturvedi, S.K., Khan, J.M., Siddiqi, M.K., Alam, P., Khan, R.H., Comparative insight into surfactants mediated amyloidogenesis of lysozyme. Int. J. Biol. Macromol. 83 (2016), 315–325.
34. [34] Zhu, W., Peng, J.M., Ge, Z.Z., Li, C.M., A-type dimeric epigallocatechin-3-gallate (EGCG) is a more potent inhibitor against the formation of insulin amyloid fibril than EGCG monomer. Biochimie 125 (2016), 204–212.
35. [35] Chaturvedi, S.K., Siddiqi, M.K., Alam, P., Khan, R.H., Protein misfolding and aggregation: mechanism, factors and detection. Process Biochem. 51 (2016), 1183–1192.
36. [36] Chaturvedi, S.K., Alam, P., Khan, J.M., Siddiqui, M.K., Kalaiarasan, P., Subbarao, N., Ahmad, Z., Khan, R.H., Biophysical insight into the anti-amyloidogenic behavior of taurine. Int. J. Biol. Macromol. 80 (2015), 375–384.
37. [37] Chaturvedi, S.K., Zaidi, N., Alam, P., Khan, J.M., Qadeer, A., Siddique, I.A., Asmat, S., Zaidi, Y., Khan, R.H., Unraveling comparative anti-amyloidogenic behavior of pyrazinamide and D-cycloserine: a mechanistic biophysical insight. PLoS One, 10, 2015, e0136528.
38. [38] Oskarsson, M.E., Paulsson, J.F., Schultz, S.W., Ingelsson, M., Westermark, P., Westermark, G.T., In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am. J. Pathol. 185 (2015), 834–846.
39. [39] Khan, J.M., Qadeer, A., Chaturvedi, S.K., Ahmad, E., Rehman, S.A.A., Gourinath, S., Khan, R.H., SDS can be utilized as an amyloid inducer: a case study on diverse proteins. PLoS One, 7, 2012, e29694.
40. [40] Siddiqi, M.K., Alam, P., Chaturvedi, S.K., Shahein, Y.E., Khan, R.H., Mechanisms of protein aggregation and inhibition. Front. Biosci. Elite 9 (2016), 1–20.
41. [41] Alam, P., Chaturvedi, S.K., Anwar, T., Siddiqi, M.K., Ajmal, M.R., Badr, G., Mahmoud, M.H., Khan, R.H., Biophysical and molecular docking insight into the interaction of cytosine b-D Arabinofuranoside with Human serum albumin. J. Lumin. 164 (2015), 123–130.
42. [42] Chaturvedi, S.K., Ahmad, E., Khan, J.M., Alam, P., Ishtikhar, M., Khan, R.H., Elucidating the interaction of limonene with bovine serum albumin: a multi-technique approach. Mol. Biosyst. 11 (2015), 307–316.
43. [43] Zaidi, N., Nusrat, S., Zaidi, F.K., Khan, R.H., pH-dependent differential interacting mechanisms of sodium dodecyl sulfate with bovine serum fetuin: a biophysical insight. J. Phys. Chem. B 118 (2014), 13025–13036.
44. [44] Nusrat, S., Siddiqi, M.K., Zaman, M., Zaidi, N., Ajmal, M.R., Alam, P., Qadeer, A., Abdelhameed, A.S., Khan, R.H., A comprehensive spectroscopic and computational investigation to probe the interaction of antineoplastic drug nordihydroguaiaretic acid with serum albumins. PLoS One, 11, 2016, e0158833.
45. [45] Ma, X., Yan, J., Wang, Q., Wu, D., Li, H., Spectroscopy study and co-administration effect on the interaction of mycophenolic acid and human serum albumin. Int. J. Biol. Macromol. 77 (2015), 280–286.
46. [46] Ajmal, M.R., Zaidi, N., Alam, P., Nusrat, S., Siddiqi, M.K., Badr, G., Mahmoud, M.H., Khan, R.H., Insight into the Interaction of antitubercular and anticancer compound Clofazimine with Human Serum Albumin: spectroscopy and molecular modelling. J. Biomol. Struct. Dyn., 2015, 1–42.
47. [47] Alam, P., Naseem, F., Abdelhameed, A.S., Khan, R.H., Effect of galactose on acid induced molten globule state of Soybean Agglutinin: biophysical approach. J. Mol. Struct. 1099 (2015), 149–153.
48. [48] Alam, P., Chaturvedi, S.K., Siddiqi, M.K., Rajpoot, R.K., Ajmal, M.R., Zaman, M., Khan, R.H., Vitamin k3 inhibits protein aggregation: implication in the treatment of amyloid diseases. Sci. Rep., 6, 2016, 26759.
49. [49] Usmani, S.M., Zirafi, O., Muller, J.A., Sandi-Monroy, N.L., Yadav, J.K., Meier, C., Weil, T., Roan, N.R., Greene, W.C., Walther, P., Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Nat. Commun. 5 (2014), 1–8.